turps the info' I read appears to be a poster at a pain conference however I would imagine the coy would be busy working on an oxymorphone paper where the reviewers would believe the results could be replicated . If this comes to pass the oxym' patch could indeed be an attractive proposition to potential partners . The esoterics of technical development !!
Ann: FDA meeting provides guidance for TPM/Oxymorphone patch, page-38
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 90918113 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 58054085 | 14 |
View Market Depth
| Last trade - 10.00am 23/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable